<DOC>
	<DOCNO>NCT00004250</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Infusing chemotherapy tumor area may kill tumor cell cause less damage healthy tissue . PURPOSE : This phase II trial study isolated limb infusion chemotherapy see well work treat patient melanoma soft tissue sarcoma arm leg remove surgery .</brief_summary>
	<brief_title>Isolated Limb Infusion Chemotherapy Treating Patients With Melanoma Soft Tissue Sarcoma Arm Leg That Can Be Removed By Surgery</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy isolated limb infusion ( ILI ) melphalan dactinomycin patient primary recurrent , unresectable regional melanoma soft tissue sarcoma extremity . - Determine morbidity patient treat regimen . - Determine expression melanoma-associated antigen well cellular humoral immune response antigens patient regional disease . OUTLINE : Patients undergo fluoroscopic placement angiographic arterial venous catheter appropriate extremity . After limb warm , melphalan dactinomycin rapidly infuse isolated limb via arterial catheter . Melphalan dactinomycin recirculated 20 minute . Patients little response 8 week may receive 2 additional treatment discretion treat physician . Patients follow 1-2 week , 3-4 week , 6-8 week , every 3-6 month thereafter deem necessary treating physician . PROJECTED ACCRUAL : A total 35 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Dactinomycin</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven primary recurrent , regional melanoma soft tissue sarcoma amenable surgical resection Majority ( great 95 % ) disease must distal apex femoral triangle lower limb deltoid insertion upper limb Bidimensionally measurable disease extremity Patients disease beyond limb eligible extremity disease require palliative treatment judgment physician PATIENT CHARACTERISTICS : Age : Over 18 Performance status : Karnofsky 70100 % Life expectancy : At least 6 month Hematopoietic : WBC least 3,000/mm^3 Hepatic : Not specify Renal : Creatinine le 2.0 mg/dL Cardiovascular : Must palpable femoral/axillary , dorsalis pedis/popliteal , radial pulse extremity treat No sign symptom vascular insufficiency ( history claudication ischemic peripheral vascular disease ) Other : Not pregnant nursing Negative pregnancy test No concurrent serious illness No severe diabetes No prior extremity complication due diabetes PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other At least 4 week since prior antitumor therapy recover At least 2 week since prior antibiotic</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>stage III adult soft tissue sarcoma</keyword>
	<keyword>recurrent adult soft tissue sarcoma</keyword>
	<keyword>stage III melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
	<keyword>stage IV adult soft tissue sarcoma</keyword>
</DOC>